image credit: Unsplash

FDA Approves Esperion’s Nexlizet for Lowering LDL-Cholesterol

February 27, 2020

Via: BioSpace

The U.S. Food and Drug Administration (FDA) approved Ann Arbor, Michigan-based Esperion’s Nexlizet (bempedoic acid and ezetimibe) for lowering LDL-Cholesterol (LDL-C). The drug is an oral, once-daily, non-statin indicated with diet and maximally tolerated statins for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional help lowering LDL-C.

Last week, the agency approved Nexletol (bempedoic acid) for the same indications.

Read More on BioSpace